Advertisement

Vitiligo pp 353-379 | Cite as

Medical Therapies

  • Alain TaïebEmail author
Chapter

Abstract

Medical therapies of vitiligo have a twofold aim: stopping inflammation and regenerating pigment cells. So far, the first aim has been generally fulfilled for short periods with courses of systemic corticosteroids or with only topical anti-inflammatory drugs for limited vitiligo. Maintenance treatment for long term control of microinflammation remains more problematic since this issue has not been addressed convincingly in large studies. The second aim relies mostly on phototherapies, which can also participate to the control of microinflammation. The most effective medical approaches combine anti-inflammatory and regenerative strategies. After psoriasis and atopic dermatitis, new targeted and semi targeted therapies (such as JAK inhibitors) are currently in development for vitiligo and alopecia areata.

References

  1. 1.
    Schake H, Rehwinkel H, Asadullah K, Cato AC. Insight into the molecular mechanisms of glucocorticoid receptor action promotes identification of novel ligands with an improved therapeutic index. Exp Dermatol. 2006;15:565–73.CrossRefGoogle Scholar
  2. 2.
    Clayton R. A double-blind trial of 0.05% clobetasol propionate in the treatment of vitiligo. Br J Dermatol. 1977;96:71–3.CrossRefGoogle Scholar
  3. 3.
    Kandil E. Treatment of vitiligo with 0.1% betamethasone 17-valerate in isopropyl alcohol-a double-blind trial. Br J Dermatol. 1974;91:457–60.CrossRefGoogle Scholar
  4. 4.
    Westerhof W, Nieuweboer-Krobotova L, Mulder PGH, et al. Left-Right comparison study of the combination of fluticasone propionate and UV-A vs either fluticasone propionate or UV-A alone for the long-term treatment of vitiligo. Arch Dermatol. 1999;135:1061–6.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Njoo MD, Spuls PI, Bos JD, et al. Nonsurgical repigmentation therapies in vitiligo. Meta-analysis of the literature. Arch Dermatol. 1998;134:1532–40.PubMedGoogle Scholar
  6. 6.
    Bleehen SS. The treatment of vitiligo with topical steroids. Light and electronmicroscopic studies. Br J Dermatol. 1976;94(S12):43–50.CrossRefGoogle Scholar
  7. 7.
    Koopmans-van Dorp B, Goedhart-van Dijk B, Neering H, et al. Treatment of vitiligo by local application of betamethasone 17-valerate in a dimethyl sulfoxide cream base. Dermatologica. 1973;146:310–4.CrossRefGoogle Scholar
  8. 8.
    Kumari J. Vitiligo treated with topical clobetasol propionate. Arch Dermatol. 1984;120:631–5.CrossRefGoogle Scholar
  9. 9.
    Schaffer JV, Bolognia JL. The treatment of hypopigmentation in children. Clin Dermatol. 2003;21:296–310.CrossRefGoogle Scholar
  10. 10.
    Khalid M, Mujtaba G, Haroon TS. Comparison of 0.05% clobetasol propionate cream and topical Puvasol in childhood vitiligo. Int J Dermatol. 1995;34:203–5.CrossRefGoogle Scholar
  11. 11.
    Coskun B, Saral Y, Turgut D. Topical 0.05% clobetasol propionate versus 1% pimecrolimus ointment in vitiligo. Eur J Dermatol. 2005;15:88–91.PubMedGoogle Scholar
  12. 12.
    Lepe V, Moncada B, Castanedo-Cazares JP, et al. A double-blind randomized trial of 0.1% tacrolimus vs 0.05% clobetasol for the treatment of childhood vitiligo. Arch Dermatol. 2003;139:581–5.CrossRefGoogle Scholar
  13. 13.
    Kumaran MS, Kaur I, Kumar B. Effect of topical calcipotriol, betamethasone dipropionate and their combination in the treatment of localized vitiligo. J Eur Acad Dermatol Venereol. 2006;20:269–73.CrossRefGoogle Scholar
  14. 14.
    Bayoumi W, Fontas E, Sillard L, Le Duff F, Ortonne JP, Bahadoran P, Lacour JP, Passeron T. Effect of a preceding laser dermabrasion on the outcome of combined therapy with narrowband ultraviolet B and potent topical steroids for treating nonsegmental vitiligo in resistant localizations. Br J Dermatol. 2012;166(1):208–11.  https://doi.org/10.1111/j.1365-2133.2011.10564.x.CrossRefGoogle Scholar
  15. 15.
    Lee L, Wu Y, Li L, Sun Y, Qiu L, Gao XH, Chen HD. Triple combination treatment with fractional CO2 laser plus topical betamethasone solution and narrowband ultraviolet B for refractory vitiligo: a prospective, randomized half-body, comparative study. Dermatol Ther. 2015;28:131–4.CrossRefGoogle Scholar
  16. 16.
    Geraldez CB, Gutierrez GT. A clinical trial of clobetasol propionate in Filipino vitiligo patients. Clin Ther. 1987;9:474–982.PubMedGoogle Scholar
  17. 17.
    Kwinter J, Pelletier J, Khambalia A, et al. High-potency steroid use in children with vitiligo: a retrospective study. J Am Acad Dermatol. 2007;56:236–41.CrossRefGoogle Scholar
  18. 18.
    Kwon HB, Choi Y, Kim HJ, Lee AY. The therapeutic effects of a topical tretinoin and corticosteroid combination for vitiligo: a placebo-controlled, paired-comparison, left-right study. J Drugs Dermatol. 2013;12:e63–7.PubMedGoogle Scholar
  19. 19.
    Fleischer AB, Ling M, Eichenfield L, et al. Tacrolimus ointment for the treatment of atopic dermatitis is not associated with an increase in cutaneous infections. J Am Acad Dermatol. 2002;47:562–70.CrossRefGoogle Scholar
  20. 20.
    Kostovic K, Pasic A. New treatment modalities for vitiligo: focus on topical immunomodulators. Drugs. 2005;65:447–59.CrossRefGoogle Scholar
  21. 21.
    Qureshi AA, Fischer MA. Topical calcineurin inhibitors for atopic dermatitis: balancing clinical benefit and possible risks. Arch Dermatol. 2006;142:633–7.CrossRefGoogle Scholar
  22. 22.
    Silverberg NB, Lin P, Travis L, et al. Tacrolimus ointment promotes repigmentation of vitiligo in children: a review of 57 cases. J Am Acad Dermatol. 2004;51:760–6.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Soter NA, Fleischer AB, Webster GF, et al. Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: part II, safety. J Am Acad Dermatol. 2001;44:S39–46.CrossRefGoogle Scholar
  24. 24.
    Wolff K. Pimecrolimus 1% cream for the treatment of atopic dermatitis. Skin Therapy Lett. 2005;10:1–6.PubMedGoogle Scholar
  25. 25.
    Mayoral FA, Vega JM, Stavisky H, et al. Retrospective analysis of pimecrolimus cream 1% for treatment of facial vitiligo. J Drugs Dermatol. 2007;6:517–21.PubMedGoogle Scholar
  26. 26.
    Souza Leite RM, Craveiro Leite AA. Two therapeutic challenges: periocular and genital vitiligo in children successfully treated with pimecrolimus cream. Int J Dermatol. 2007;46:986–9.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Allen A, Siegfried E, Silverman R, et al. Significant absorption of topical tacrolimus in 3 patients with Netherton syndrome. Arch Dermatol. 2001;137:747–50.PubMedPubMedCentralGoogle Scholar
  28. 28.
    Grimes PE, Morris R, Avaniss-Aghajani E, et al. Topical tacrolimus therapy for vitiligo: therapeutic responses and skin messenger RNA expression of proinflammatory cytokines. J Am Acad Dermatol. 2004;51:52–61.CrossRefGoogle Scholar
  29. 29.
    Lan CC, Chen GS, Chiou MH, et al. FK506 promotes melanocyte and melanoblast growth and creates a favourable milieu for cell migration via keratinocytes: possible mechanisms of how tacrolimus ointment induces repigmentation in patients with vitiligo. Br J Dermatol. 2005;153:498–505.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Kang HY, Choi YM. FK506 increases pigmentation and migration of human melanocytes. Br J Dermatol. 2006;155:1037–40.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Sardana K, Bhushan P, Kumar Garg V. Effect of tacrolimus on vitiligo in absence of UV radiation exposure. Arch Dermatol. 2007;143:119–20.CrossRefGoogle Scholar
  32. 32.
    Ormerod AD. Topical tacrolimus and pimecrolimus and the risk of cancer: how much cause for concern? Br J Dermatol. 2005;153:701–5.CrossRefGoogle Scholar
  33. 33.
    Almeida P, Borrego L, Rodriguez-Lopez J, et al. [Vitiligo. Treatment of 12 cases with topical tacrolimus]. Actas Dermosifiliogr. 2005;96:159–163.Google Scholar
  34. 34.
    Ho N, Pope E, Weinstein M, Greenberg S, Webster C, Krafchik BR. A double-blind, randomized, placebo-controlled trial of topical tacrolimus 0.1% vs. clobetasol propionate 0.05% in childhood vitiligo. Br J Dermatol. 2011;165:626–32.CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Gan EY, Taïeb A. Unwanted lentigines after topical tacrolimus for vitiligo. Australas J Dermatol. 2017;58(4):e259–60.CrossRefGoogle Scholar
  36. 36.
    Sendur N, Karaman G, Sanic N, Savk E. Topical pimecrolimus: a new horizon for vitiligo treatment? J Dermatolog Treat. 2006;17:338–42.CrossRefGoogle Scholar
  37. 37.
    Radakovic S, Breier-Maly J, Konschitzky R, Kittler H, Sator P, Hoenigsmann H, Tanew A. Response of vitiligo to once- vs. twice-daily topical tacrolimus: a controlled prospective, randomized, observer-blinded trial. J Eur Acad Dermatol Venereol. 2009;23:951–3.CrossRefGoogle Scholar
  38. 38.
    Boone B, Ongenae K, Van Geel N, et al. Topical pimecrolimus in the treatment of vitiligo. Eur J Dermatol. 2007;17:55–61.PubMedGoogle Scholar
  39. 39.
    Seirafi H, Farnaghi F, Firooz A, et al. Pimecrolimus cream in repigmentation of vitiligo. Dermatology. 2007;214:253–9.CrossRefGoogle Scholar
  40. 40.
    Castanedo-Cazares JP, Lepe V, Moncada B. Repigmentation of chronic vitiligo lesions by following tacrolimus plus ultraviolet-B-narrow-band. Photodermatol Photoimmunol Photomed. 2003;19:35–6.CrossRefGoogle Scholar
  41. 41.
    Ostovari N, Passeron T, Lacour JP, Ortonne JP. Lack of efficacy of tacrolimus in the treatment of vitiligo in the absence of UV-B exposure. Arch Dermatol. 2006;142:252–3.CrossRefGoogle Scholar
  42. 42.
    Passeron T, Ostovari N, Zakaria W, et al. Topical tacrolimus and the 308-nm excimer laser: a synergistic combination for the treatment of vitiligo. Arch Dermatol. 2004;140:1065–9.PubMedPubMedCentralGoogle Scholar
  43. 43.
    Dawid M, Veensalu M, Grassberger M, Wolff K. Efficacy and safety of pimecrolimus cream 1% in adult patients with vitiligo: results of a randomized, double-blind, vehicle-controlled study. J Dtsch Dermatol Ges. 2006;4:942–6.CrossRefGoogle Scholar
  44. 44.
    Fai D, Cassano N, Vena GA. Narrow-band UVB phototherapy combined with tacrolimus ointment in vitiligo: a review of 110 patients. J Eur Acad Dermatol Venereol. 2007;21:916–20.CrossRefGoogle Scholar
  45. 45.
    Luger T, Boguniewicz M, Carr W, Cork M, Deleuran M, Eichenfield L, Eigenmann P, Fölster-Holst R, Gelmetti C, Gollnick H, Hamelmann E, Hebert AA, Muraro A, Oranje AP, Paller AS, Paul C, Puig L, Ring J, Siegfried E, Spergel JM, Stingl G, Taieb A, Torrelo A, Werfel T, Wahn U. Pimecrolimus in atopic dermatitis: consensus on safety and the need to allow use in infants. Pediatr Allergy Immunol. 2015;26:306–15.CrossRefPubMedPubMedCentralGoogle Scholar
  46. 46.
    Mayoral FA, Gonzalez C, Shah NS, Arciniegas C. Repigmentation of vitiligo with pimecrolimus cream: a case report. Dermatology. 2003;207:322–3.CrossRefGoogle Scholar
  47. 47.
    Cavalié M, Ezzedine K, Fontas E, Montaudié H, Castela E, Bahadoran P, Taïeb A, Lacour JP, Passeron T. Maintenance therapy of adult vitiligo with 0.1% tacrolimus ointment: a randomized, double blind, placebo-controlled study. J Invest Dermatol. 2015;135:970–4.CrossRefPubMedPubMedCentralGoogle Scholar
  48. 48.
    Grimes PE, Soriano T, Dytoc MT. Topical tacrolimus for repigmentation of vitiligo. J Am Acad Dermatol. 2002;47:789–91.CrossRefGoogle Scholar
  49. 49.
    Kalek AZ, Spencer JM, Phelps RG. Combined excimer laser and topical tacrolimus for the treatment of vitiligo: a pilot study. Dermatol Surg. 2004;30:130–5.Google Scholar
  50. 50.
    Mehrabi D, Pandya AG. A randomized, placebo-controlled, double-blind trial comparing narrowband UV-B Plus 0.1% tacrolimus ointment with narrowband UV-B plus placebo in the treatment of generalized vitiligo. Arch Dermatol. 2006;142:927–9.CrossRefPubMedPubMedCentralGoogle Scholar
  51. 51.
    Kanwar AJ, Dogra S, Parsad D. Topical tacrolimus for treatment of childhood vitiligo in Asians. Clin Exp Dermatol. 2004;29:589–92.CrossRefPubMedPubMedCentralGoogle Scholar
  52. 52.
    Van Geel N, Speeckaert R, Mollet I, De Schepper S, De Wolf J, Tjin EP, Luiten RM, Lambert J, Brochez L. In vivo vitiligo induction and therapy model: double-blind, randomized clinical trial. Pigment Cell Melanoma Res. 2012;25:57–65.CrossRefGoogle Scholar
  53. 53.
    Hartmann A, Brocker EB, Hamm H. Occlusive treatment enhances efficacy of tacrolimus 0.1% ointment in adult patients with vitiligo: results of a placebo-controlled 12 month prospective study. Acta Derm Venereol. 2008;88:474–9.CrossRefGoogle Scholar
  54. 54.
    Bakos L, Bakos RM. Focal acne during topical tacrolimus therapy for vitiligo. Arch Dermatol. 2007;143:1223–4.PubMedGoogle Scholar
  55. 55.
    DDe D, Kanwar AJ. Tacrolimus-induced hyperpigmentation in a patch of vitiligo. Skinmed. 2008;7:93–4.CrossRefGoogle Scholar
  56. 56.
    Birlea SA, Costin GE, Norris DA. Cellular and molecular mechanisms involved in the action of vitamin D analogs targeting vitiligo depigmentation. Curr Drug Targets. 2008;9:345–59.CrossRefGoogle Scholar
  57. 57.
    Guilhou JJ. The therapeutic effects of vitamin D3 and its analogues in psoriasis. Expert Opin Investig Drugs. 1998;7:77–84.CrossRefGoogle Scholar
  58. 58.
    Ortonne JP, Kaufmann R, Lecha M, Goodfield M. Efficacy of treatment with calcipotriol/betamethasone dipropionate followed by calcipotriol alone compared with tacalcitol for the treatment of psoriasis vulgaris: a randomised, double-blind trial. Dermatology. 2004;209:308–13.CrossRefGoogle Scholar
  59. 59.
    Takahashi H, Ibe M, Kinouchi M, et al. Similarly potent action of 1,25-dihydroxyvitamin D3 and its analogues, tacalcitol, calcipotriol, and maxacalcitol on normal human keratinocyte proliferation and differentiation. J Dermatol Sci. 2003;31:21–8.CrossRefGoogle Scholar
  60. 60.
    Watabe H, Soma Y, Kawa Y, et al. Differentiation of murine melanocyte precursore induced by 1,25 dihydroxyvitamin D3 is associated with the stimulation of endothelin B receptor expression. J Invest Dermatol. 2002;119:583–9.CrossRefGoogle Scholar
  61. 61.
    Gawkrodger DJ, Ormerod AD, Shaw L, et al. Guideline for the diagnosis and management of vitiligo. Br J Dermatol. 2008;159:1051–76.CrossRefPubMedPubMedCentralGoogle Scholar
  62. 62.
    Lotti T, Buggiani G, Troiano M, et al. Targeted and combination treatments for vitiligo. Comparative evaluation of different current modalities in 458 subjects. Dermatol Ther. 2008;21(1):s20–6.CrossRefGoogle Scholar
  63. 63.
    Parsad D, Saini R, Nagpal R. Calcipotriol in vitiligo: a preliminary study. Pediatr Dermatol. 1999;16:317–20.CrossRefGoogle Scholar
  64. 64.
    Cherif F, Azaiz MI, Ben Hamida A, et al. Calcipotriol and PUVA as treatment for vitiligo. Dermatol Online J. 2003;9:4.PubMedGoogle Scholar
  65. 65.
    Ermis O, Alpsoy E, Cetin L, Yilmaz E. Is the efficacy of psoralen plus ultraviolet A therapy for vitiligo enhanced by concurrent topical calcipotriol? A placebo-controlled double-blind study. Br J Dermatol. 2001;145:472–5.CrossRefPubMedPubMedCentralGoogle Scholar
  66. 66.
    Katayama I, Ashida M, Maeda A, et al. Open trial of topical tacalcitol [1alpha24(OH)2D3] and solar irradiation for vitiligo vulgaris: upregulation of cKit mRNA by cultured melanocytes. Eur J Dermatol. 2003;13:372–6.PubMedGoogle Scholar
  67. 67.
    Baysal V, Vildirim M, Erel A, Kesici D. Is the combination of calcipotriol and PUVA effective in vitiligo? J Eur Acad Dermatol Venereol. 2003;17:299–302.CrossRefPubMedPubMedCentralGoogle Scholar
  68. 68.
    Goktas EO, Aydin F, Senturk N, et al. Combination of narrow band UVB and topical calcipotriol for the treatment of vitiligo. J Eur Acad Dermatol Venereol. 2006;20:553–7.CrossRefPubMedPubMedCentralGoogle Scholar
  69. 69.
    Kullavanijaya P, Lim HW. Topical calcipotriene and narrowband ultraviolet B in the treatment of vitiligo. Photodermatol Photoimmunol Photomed. 2004;20:248–51.CrossRefPubMedPubMedCentralGoogle Scholar
  70. 70.
    Leone G, Pacifico A, Iacovelli P, et al. Tacalcitol and narrow-band phototherapy in patients with vitiligo. Clin Exp Dermatol. 2006;31:200–5.CrossRefPubMedPubMedCentralGoogle Scholar
  71. 71.
    Ada S, Sahin S, Boztepe G, et al. No additional effect of topical calcipotriol on narrow-band UVB phototherapy in patients with generalized vitiligo. Photodermatol Photoimmunol Photomed. 2005;21:79–83.CrossRefPubMedPubMedCentralGoogle Scholar
  72. 72.
    Lu-yan T, Wen-wen F, Lei-hong X, et al. Topical tacalcitol and 308-nm monochromatic excimer light: a synergistic combination for the treatment of vitiligo. Photodermatol Photoimmunol Photomed. 2006;22:310–4.CrossRefPubMedPubMedCentralGoogle Scholar
  73. 73.
    Goldinger SM, Dummer R, Schmid P, et al. Combination of 308-nm xenon chloride excimer laser and topical calcipotriol in vitiligo. J Eur Acad Dermatol Venereol. 2007;21:504–8.PubMedPubMedCentralGoogle Scholar
  74. 74.
    Hartmann A, Lurz C, Hamm H, et al. Narrow-band UVB311 nm vs. broad-band UVB therapy in combination with topical calcipotriol vs. placebo in vitiligo. Int J Dermatol. 2005;44:736–42.CrossRefGoogle Scholar
  75. 75.
    Rodriguez-Martìn M, Garcia Bustinduy M, Saez Rodriguez M, Noda Cabrera A. Randomized, double-blind clinical trial to evaluate the efficacy of topical tacalcitol and sunlight exposure in the treatment of adult nonsegmental vitiligo. Br J Dermatol. 2009;160:409–14.CrossRefGoogle Scholar
  76. 76.
    Khullar G, Kanwar AJ, Singh S, Parsad D. Comparison of efficacy and safety profile of topical calcipotriol ointment in combination with NB-UVB vs. NB-UVB alone in the treatment of vitiligo: a 24-week prospective right-left comparative clinical trial. J Eur Acad Dermatol Venereol. 2015;29(5):925–32.CrossRefPubMedPubMedCentralGoogle Scholar
  77. 77.
    Sahu P, Jain VK, Aggarwal K, Kaur S, Dayal S. Tacalcitol: a useful adjunct to narrow band ultraviolet-B phototherapy in vitiligo. Photodermatol Photoimmunol Photomed. 2016.  https://doi.org/10.1111/phpp.12265.
  78. 78.
    Amano H, Abe M, Ishikawa O. First case report of topical tacalcitol for vitiligo repigmentation. Pediatr Dermatol. 2008;25:262–4.CrossRefGoogle Scholar
  79. 79.
    Gargoom AM, Duweb GA, Elzorghany AH, et al. Calcipotriol in the treatment of childood vitiligo. Int J Clin Pharmacol Res. 2004;24:11–4.PubMedGoogle Scholar
  80. 80.
    Kumaran MS, Kaur I, Kumar B. Effect of topical calcipotriol, betamethasone dipropionate and their combinattion in the treatment of localized vitiligo. J Eur Acad Dermatol Venereol. 2006;20:269–73.CrossRefGoogle Scholar
  81. 81.
    Travis LB, Silverberg NB. Calcipotriene and corticosteroids combination therapy for vitiligo. Pediatr Dermatol. 2004;21(4):495–8.CrossRefGoogle Scholar
  82. 82.
    Leone G, Pacifico A. Profile of clinical efficacy and safety of topical tacalcitol. Acta Biomed. 2005;76:13–9.PubMedPubMedCentralGoogle Scholar
  83. 83.
    Ameen M, Exarchou V, Chu AC. Topical calcipotriol as monotherapy and in combination with psoralen plus ultraviolet A in the treatment of vitiligo. Br J Dermatol. 2001;145:476–9.CrossRefPubMedPubMedCentralGoogle Scholar
  84. 84.
    Arca E, Tastan HB, Erbil AH, et al. Narrow-band ultraviolet B as monotherapy and in combination with topical calcipotriol in the treatment of vitiligo. J Dermatol. 2006;33:338–43.CrossRefPubMedPubMedCentralGoogle Scholar
  85. 85.
    Chiaverini C, Passeron T, Ortonne JP. Treatment of vitiligo by topical calcipotriol. J Eur Acad Dermatol Venereol. 2002;16:137–8.CrossRefPubMedPubMedCentralGoogle Scholar
  86. 86.
    Akyol M, Celik VK, Ozcelik S, et al. The effects of vitamin E on the skin lipid peroxidation and the clinical improvement in vitiligo patients treated with PUVA. Eur J Dermatol. 2002;12:24–6.PubMedPubMedCentralGoogle Scholar
  87. 87.
    Dell’Anna ML, Mastrofrancesco A, Sala R, et al. Anrtioxidants and narrow band-UVB in the treatment of vitiligo: a double-blind placebo controlled trial. Clin Exp Dermatol. 2007;32:631–6.CrossRefPubMedPubMedCentralGoogle Scholar
  88. 88.
    Schallreuter KU, Wood JM, Lemke KR, et al. Treatment of vitiligo with a topical application of pseudocatalase and calcium in combination with short-term UVB exposure: a case study on 33 patients. Dermatology. 1995;190:223–9.CrossRefGoogle Scholar
  89. 89.
    Dell’Anna ML, Ottaviani M, Kovacs D, et al. Energetic mitochondrial failing in vitiligo and possible rescue by cardiolipin. Sci Rep. 2017;7(1):13663.CrossRefPubMedPubMedCentralGoogle Scholar
  90. 90.
    Naini FF, Shooshtari AV, Ebrahimi B, Molaei R. The effect of pseudocatalase/superoxide dismutase in the treatment of vitiligo: a pilot study. J Res Pharm Pract. 2012;1:77–80.CrossRefPubMedPubMedCentralGoogle Scholar
  91. 91.
    Schallreuter KU, Moore J, Behrens-Williams S, et al. Rapid initiation of repigmentation in vitiligo with dead sea climatotherapy in combination with pseudocatalase (PC-KUS). Int J Dermatol. 2002;41:482–7.CrossRefGoogle Scholar
  92. 92.
    Gibbons NCJ, Wood JM, Rokos H, et al. Computer simulation of native epidermal enzyme structure in the presence and absence of hydrogen peroxide (H2O2): potential and pitfalls. J Invest Dermatol. 2006;126:2576–82.CrossRefGoogle Scholar
  93. 93.
    Bakis-Petsoglou S, Le Guay JL, Wittal R. A randomized, double-blinded, placebo-controlled trial of pseudocatalase cream and narrowband ultraviolet B in the treatment of vitiligo. Br J Dermatol. 2009;161:910–7.CrossRefPubMedPubMedCentralGoogle Scholar
  94. 94.
    Patel DC, Evans AV, Hawk JL. Topical pseudocatalase mousse and narrowband UVB phototherapy is not effective for vitiligo: an open single-center study. Clin Exp Dermatol. 2002;27:641–4.CrossRefPubMedPubMedCentralGoogle Scholar
  95. 95.
    Schallreuter KU, Kruger C, Wurfel C, et al. From basic research to the bedside: efficacy of topical treatment with psudocatalase PC-KUS in 71 children with vitiligo. Int J Dermatol. 2008;47:743–53.CrossRefGoogle Scholar
  96. 96.
    Vouldoukis I, Lacan D, Kamate C, et al. Antioxidant and antinflammatory properties of a Cucumis melo LC. extract rich in superoxido dismutase activity. J Ethnopharmacol. 2004;94:67–75.CrossRefGoogle Scholar
  97. 97.
    Khemis A, Ortonne JP. Comparative study of a vegetable extract with superoxide dismutase and catalase (Vitix®) plus selective UVB phototherapy versus excipient plus selective UVB phototherapy in the treatment of vitiligo vulgaris. Les Nouv Dermatol. 2004;23:45–6.Google Scholar
  98. 98.
    Schallreuter KU, Rokos H. Vitix®- a new treatment for vitiligo? Int J Dermatol. 2005;44:969–70.CrossRefGoogle Scholar
  99. 99.
    Yuksel EP, Aydin F, Senturk N, Canturk T, Turanli AY. Comparison of the efficacy of narrow band ultraviolet B and narrow band ultraviolet B plus topical catalase-superoxide dismutase treatment in vitiligo patients. Eur J Dermatol. 2009;19:341–4.PubMedGoogle Scholar
  100. 100.
    Farah FS, Kurban AK, Chaglassian HT. The treatment of vitiligo with psoralens and triamcinolone by mouth. Br J Dermatol. 1967;79:89–91.CrossRefGoogle Scholar
  101. 101.
    Pasricha JS, Seetharam KA, Dashore A. Evaluation of five different regimes for the treatment of vitiligo. Indian J Dermatol Venereol Leprol. 1989;55:18–21.PubMedGoogle Scholar
  102. 102.
    Pasricha JS. Pulse therapy as a cure for autoimmune diseases. Indian J Dermatol Venereol Leprol. 2003;69:323–8.PubMedGoogle Scholar
  103. 103.
    Kountz SL, Cohn R. Initial treatment of renal allografts with large intrarenal doses of immunosuppressive drugs. Lancet. 1969;1:338–40.CrossRefGoogle Scholar
  104. 104.
    Pasricha JS, Kumrah L. Alopecia totalis treated with oral mini-pulse (OMP) therapy with betamethasone. Indian J Dermatol Venereol Leprol. 1996;62:106–9.PubMedGoogle Scholar
  105. 105.
    Joshi A, Khaitan BK, Verma KK, Singh MK. Generalized and bullous lichen planus treated successfully with oral mini-pulse therapy. Indian J Dermatol Venereol Leprol. 1999;65:303–4.PubMedGoogle Scholar
  106. 106.
    Mittal R, Khaitan BK, Sirka CS. Trachyonychia treated with oral minipulse therapy. Indian J Dermatol Venereol Leprol. 2001;67:202–3.PubMedGoogle Scholar
  107. 107.
    Verma K, Verma KK. Infantile periocular haemangioma treated with two days in a week betamethasone oral mini pulse therapy. Indian J Pediatr. 2001;68:355–6.CrossRefGoogle Scholar
  108. 108.
    Pasricha JS, Khaitan BK. Oral mini-pulse therapy with betamethasone in vitiligo patients having extensive or fast-spreading disease. Int J Dermatol. 1993;32:753–7.CrossRefGoogle Scholar
  109. 109.
    Kanwar AJ, Dhar S, Dawn G. Oral minipulse therapy in vitiligo. Dermatology. 1995;190:251–2.CrossRefGoogle Scholar
  110. 110.
    Radakovic- Fijan S, Firnsinn-Friedl AM, Honigsmann H, et al. Oral dexamethasone pulse treatment for vitiligo. J Am Acad Dermatol. 2001;44:814–7.CrossRefGoogle Scholar
  111. 111.
    Kanwar AJ, Mahajan R, Parsad D. Low-dose oral mini-pulse dexamethasone therapy in progressive unstable vitiligo. J Cutan Med Surg. 2013;17:259–68.CrossRefGoogle Scholar
  112. 112.
    Singh A, Kanwar AJ, Parsad D, Mahajan R. Randomized controlled study to evaluate the effectiveness of dexamethasone oral minipulse therapy versus oral minocycline in patients with active vitiligo vulgaris. Indian J Dermatol Venereol Leprol. 2014;80:29–35.CrossRefGoogle Scholar
  113. 113.
    El Mofty M, Essmat S, Youssef R, Sobeih S, Mahgoub D, Ossama S, Saad A, El Tawdy A, Mashaly HM, Saney I, Helal R, Shaker O. The role of systemic steroids and phototherapy in the treatment of stable vitiligo: a randomized controlled trial. Dermatol Ther. 2016.  https://doi.org/10.1111/dth.12384.
  114. 114.
    Cara CJ, Pena AS, Sans M, et al. Reviewing the mechanism of action of thiopurine drugs: towards a new paradigm in clinical practice. Med Sci Monit. 2004;10:247–54.Google Scholar
  115. 115.
    Gokhale BB. Cyclophosphamide and vitiligo. Int J Dermatol. 1979;18:92.PubMedGoogle Scholar
  116. 116.
    Gokhale BB, Parakh AP. Cyclophosphamide in vitiligo. Indian J Dermatol. 1983;28:7–10.PubMedGoogle Scholar
  117. 117.
    Radmanesh M, Saedi K. The efficacy of combined PUVA and low-dose azathioprine for early and enhanced repigmentation in vitiligo patients. J Dermatolog Treat. 2006;17:151–3.CrossRefGoogle Scholar
  118. 118.
    Mahmoud BH, Hexsel CL, Hamzavi IH. An update on new and emerging options for the treatment of vitiligo. Skin Therapy Lett. 2008;13:1–6.PubMedGoogle Scholar
  119. 119.
    Singh H, Kumaran MS, Bains A, Parsad D. A randomized comparative study of oral corticosteroid minipulse and low-dose oral methotrexate in the treatment of unstable vitiligo. Dermatology. 2015;231:286–90.CrossRefGoogle Scholar
  120. 120.
    Skurkovich SV, Klinova EG, Eremkina EI, Levina NV. Immunosuppressive effect of an anti-interferon serum. Nature. 1974;247:551–2.CrossRefGoogle Scholar
  121. 121.
    Skurkovich S, Skurkovich B, Bellanti JA. A unifying model of the immunoregulatory role of the interferon system: can interferon produce disease in humans? Clin Immunol Immunopathol. 1987;43:362–73.CrossRefGoogle Scholar
  122. 122.
    Skurkovich S, Skurkuvich B (2006) Inhibition of IFN-γ as a method of treatment of various autoimmune diseases, including skin disease. In: Numerof R, Dinarello CA, Asadullah K (edts.), Cytokines as potential therapeutic targets for inflammatory skin diseases. Ernst Schering Research Foundation Workshop 58, Springer, Berlin, 1-27.Google Scholar
  123. 123.
    Anbar TS, Abdel-Rahman AT, Ahmad HM. Vitiligo occurring at site of interferon-alpha 2b injection in a patient with chronic viral hepatitis C: a case report. Clin Exp Dermatol. 2007;33:503.CrossRefGoogle Scholar
  124. 124.
    Bernstein D, Reddy KR, Jeffers L, Schiff E. Canities and vitiligo complicating interferon therapy for hepatitis C. Am J Gastroenterol. 1995;90:1176–7.PubMedPubMedCentralGoogle Scholar
  125. 125.
    Simsek H, Savas C, Akkiz H, Telatar H. Interferon-induced vitiligo in a patient with chronic viral hepatitis C infection. Dermatology. 1996;193:65–6.CrossRefPubMedPubMedCentralGoogle Scholar
  126. 126.
    Taffaro M, Pyrsopoulos N, Cedron H, et al. Vitiligo improvement in a hepatitis C patient after treatment with PEG-interferon alpha-2a and ribavirin: a case report. Dig Dis Sci. 2007;52:3435–7.CrossRefPubMedPubMedCentralGoogle Scholar
  127. 127.
    Skurkovich B, Skurkovich S. Anti-interferon-gamma antibodies in the treatment of autoimmune diseases. Curr Opin Mol Ther. 2003;5:52–7.PubMedPubMedCentralGoogle Scholar
  128. 128.
    Skurkovich S, Korotky NG, Shaova NM, Skurkovich B. Successful anti-IFN therapy of alopecia, vitiligo, and psoriasis. Clin Immunol. 2002;103:S103.Google Scholar
  129. 129.
    Ramírez-Hernández M, Marras C, Martínez-Escribano JA. Infliximab-induced vitiligo. Dermatology. 2005;210:79–80.CrossRefGoogle Scholar
  130. 130.
    Rashighi M, Agarwal P, Richmond JM, Harris TH, Dresser K, Su MW, Zhou Y, Deng A, Hunter CA, Luster AD, Harris JE. CXCL10 is critical for the progression and maintenance of depigmentation in a mouse model of vitiligo. Sci Transl Med. 2014;6:223ra23.CrossRefPubMedPubMedCentralGoogle Scholar
  131. 131.
    Agarwal P, Rashighi M, Essien KI, Richmond JM, Randall L, Pazoki-Toroudi H, Hunter CA, Harris JE. Simvastatin prevents and reverses depigmentation in a mouse model of vitiligo. J Invest Dermatol. 2015;135:1080–8.CrossRefPubMedPubMedCentralGoogle Scholar
  132. 132.
    Vanderweil SG, Amano S, Ko WC, Richmond JM, Kelley M, Senna MM, Pearson A, Chowdary S, Hartigan C, Barton B, Harris JE. A double-blind, placebo-controlled, phase-II clinical trial to evaluate oral simvastatin as a treatment for vitiligo. J Am Acad Dermatol. 2017;76:150–1.CrossRefPubMedPubMedCentralGoogle Scholar
  133. 133.
    Birol A, Kisa U, Kurtipek GS, et al. Increased tumor necrosis factor alpha (TNF-alpha) and interleukin 1 alpha (IL1-alpha) levels in the lesional skin of patients with nonsegmental vitiligo. Int J Dermatol. 2006;45:992–3.CrossRefGoogle Scholar
  134. 134.
    Moretti S, Spallanzani A, Amato L, et al. New insights into the pathogenesis of vitiligo: imbalance of epidermal cytokines at sites of lesions. Pigment Cell Res. 2002;15:87–92.CrossRefGoogle Scholar
  135. 135.
    Smith DI, Heffernan MP. Vitiligo after the resolution of psoriatic plaques during treatment with adalimumab. J Am Acad Dermatol. 2008;58:S50–1.CrossRefGoogle Scholar
  136. 136.
    Rigopoulos D, Gregoriou S, Larios G, et al. Etanercept in the treatment of vitiligo. Dermatology. 2007;215:84–5.CrossRefGoogle Scholar
  137. 137.
    Swope VB, Abdel-Malek Z, Kassem LM, Nordlund JJ. Interleukins 1 alpha and 6 and tumor necrosis factor-alpha are paracrine inhibitors of human melanocyte proliferation and melanogenesis. J Invest Dermatol. 1991;96:180–5.CrossRefPubMedPubMedCentralGoogle Scholar
  138. 138.
    Martínez-Esparza M, Jiménez-Cervantes C, Solano F, et al. Mechanisms of melanogenesis inhibition by tumor necrosis factor-alpha in B16/F10 mouse melanoma cells. Eur J Biochem. 1998;255:139–46.CrossRefGoogle Scholar
  139. 139.
    Alghamdi KM, Khurrum H, Taieb A, Ezzedine K. Treatment of generalized vitiligo with anti-TNF-α agents. J Drugs Dermatol. 2012;11:534–9.PubMedGoogle Scholar
  140. 140.
    Webb KC, Tung R, Winterfield LS, Gottlieb AB, Eby JM, Henning SW, Le Poole IC. Tumour necrosis factor-α inhibition can stabilize disease in progressive vitiligo. Br J Dermatol. 2015;173:641–50.CrossRefPubMedPubMedCentralGoogle Scholar
  141. 141.
    Fernandez-Obregon AC. Clinical management with efalizumab of a patient with psoriasis and comorbid vitiligo. J Drugs Dermatol. 2008;7:679–81.PubMedGoogle Scholar
  142. 142.
    Wakkee M, Assen YJ, Thio HB, Neumann HA. Repigmentation of vitiligo during efalizumab. J Am Acad Dermatol. 2008;59:S57–8.CrossRefGoogle Scholar
  143. 143.
    Al Badri AM, Foulis AK, Todd PM, et al. Abnormal expression of MHC class II and ICAM-1 by melanocytes in vitiligo. J Pathol. 1993;169:203–6.CrossRefGoogle Scholar
  144. 144.
    Abdallah M, Abdel-Naser MB, Moussa MH, et al. Sequential immunohistochemical study of depigmenting and repigmenting minigrafts in vitiligo. Eur J Dermatol. 2003;13:548–52.PubMedGoogle Scholar
  145. 145.
    Joshipura D, Alomran A, Zancanaro P, Rosmarin D. Treatment of vitiligo with the topical Janus kinase inhibitor ruxolitinib: a 32-week open-label extension study with optional narrow-band ultraviolet B. J Am Acad Dermatol. 2018;78:1205–7.CrossRefGoogle Scholar
  146. 146.
    Craiglow BG, King BA. Tofacitinib citrate for the treatment of vitiligo: a pathogenesis-directed therapy. JAMA Dermatol. 2015;151:1110–2.CrossRefGoogle Scholar
  147. 147.
    Liu LY, Strassner JP, Refat MA, Harris JE, King BA. Repigmentation in vitiligo using the Janus kinase inhibitor tofacitinib may require concomitant light exposure. J Am Acad Dermatol. 2017;77:675–82.CrossRefPubMedPubMedCentralGoogle Scholar
  148. 148.
    Boniface K, Jacquemin C, Darrigade AS, Dessarthe B, Martins C, Boukhedouni N, Vernisse C, Grasseau A, Thiolat D, Rambert J, Lucchese F, Bertolotti A, Ezzedine K, Taieb A, Seneschal J. Vitiligo skin is imprinted with resident memory CD8 T cells expressing CXCR3. J Invest Dermatol. 2018;138:355–64.CrossRefGoogle Scholar
  149. 149.
    Cohen BE, Elbuluk N, Mu EW, Orlow SJ. Alternative systemic treatments for vitiligo: a review. Am J Clin Dermatol. 2015;16:463–74.CrossRefGoogle Scholar
  150. 150.
    Juhlin L, Olsson MJ. Improvement of vitiligo after oral treatment with vitamin B12 and folic acid and the importance of sun exposure. Acta Derm Venereol. 1997;77:460–2.PubMedGoogle Scholar
  151. 151.
    Montes LF, Diaz ML, Lajous J, et al. Folic acid and vitamin B12 in vitiligo: a nutritional approach. Cutis. 1992;50:39–42.PubMedGoogle Scholar
  152. 152.
    Shaker OG, El-Tahlawi SMR. Is there a relationship between homocysteine and vitiligo? Br J Dermatol. 2008;159:720–4.PubMedGoogle Scholar
  153. 153.
    Tjioe M, et al. Treatment of vitiligo vulgaris with narrow band UVB (311 nm) for one year and the effect of addition of folic acid and vitamin B12. Acta Derm Venereol. 2002;82:369–72.CrossRefGoogle Scholar
  154. 154.
    Watabe A, Yamasaki K, Asano M, Kanbayashi Y, Nasu-Tamabuchi M, Terui H, Furudate S, Kakizaki A, Tsuchiyama K, Kimura Y, Ito Y, Kikuchi K, Aiba S. Efficacy of oral cholecalciferol on rhododendrol-induced vitiligo: a blinded randomized clinical trial. J Dermatol. 2018;45:456–62.CrossRefGoogle Scholar
  155. 155.
    Cormane RH, et al. Phenylalanine and UVA light for the treatment of vitiligo. Arch Dermatol Res. 1985;277:126–30.CrossRefGoogle Scholar
  156. 156.
    Rojas-Urdaneta JE, Poleo-Romero AG. Evaluation of an antioxidant and mitochondria-stimulating cream formula on the skin of patients with stable common vitiligo. Investig Clin. 2007;48:21–31.Google Scholar
  157. 157.
    Colucci R, Dragoni F, Conti R, Pisaneschi L, Lazzeri L, Moretti S. Evaluation of an oral supplement containing Phyllanthus emblica fruit extracts, vitamin E, and carotenoids in vitiligo treatment. Dermatol Ther. 2015;28:17–21.CrossRefGoogle Scholar
  158. 158.
    Parsad D, Pandhi R, Juneja A. Effectiveness of oral Gingko biloba in treating limited, slowly spreading vitiligo. Clin Exp Dermatol. 2002;28:285–7.CrossRefGoogle Scholar
  159. 159.
    Middelkamp MA, Bos JD, Riuz-Diaz F, et al. Treatment of vitiligo vulgaris with narrow-band UVB and oral Polypodium leucotomos extract: a randomized double-blind placebo-controlled study. J Eur Acad Dermatol Venereol. 2007;21:942–50.CrossRefGoogle Scholar
  160. 160.
    Hercberg S, Ezzedine K, Guinot C, et al. Antioxidant supplementation increases the risk of skin cancers in women but not in men. J Nutr. 2007;137:2098–105.CrossRefGoogle Scholar
  161. 161.
    Lim HW, Grimes PE, Agbai O, Hamzavi I, Henderson M, Haddican M, Linkner RV, Lebwohl M. Afamelanotide and narrowband UV-B phototherapy for the treatment of vitiligo: a randomized multicenter trial. JAMA Dermatol. 2015;151:42–50.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Service de DermatologieHôpital St AndréBordeauxFrance

Personalised recommendations